Labrina Barmpetaki, PIF President: “We’re not just asking for access to innovation — we’re asking for it to be properly valued and rewarded!” Pharma Innovation Forum at the Delphi Economic Forum 2026: Innovation in healthcare requires access, sustainability, and shared responsibility. Pharmaceutical innovation and especially the ability of the healthcare system to translate it into real access and value for…
The highest clawback in the EU, the suspension of innovative cancer therapies, the increasing delays in the arrival of new treatments, and disinvestment in innovation create a worrying environment that requires shared responsibility and immediate action. PhARMA Innovation Forum (PIF), representing 30 leading biopharmaceutical companies engaged in the research, development, and provision of innovative therapies,…
Pharma Innovation Forum at the Panhellenic Congress on Health Economics and Policy highlighted the critical role of data, evaluation, and European harmonization in modern pharmaceutical policy. Pharma Innovation Forum (PIF) had a strong institutional presence at the Panhellenic Congress on Health Economics and Policy, contributing substantially to the public discussion on how the country can…
Greece at a critical turning point Will Greece keep up with pharmaceutical innovation or be left behind? The event of Pharma Innovation Forum Greece (PIF), held on Wednesday, November 26, highlighted a reality that concerns us all: pharmaceutical innovation is advancing faster than ever. The question is whether Greece can -and wants to- keep up.…
The 2nd interactive workshop organized by PIF and ELLoK highlighted practical steps, institutional proposals and the importance of active citizen participation in the new era of health data. The Hellenic Cancer Federation (ELLOK), as the National Cancer Mission Hub (NCMH) of the European Mission on Cancer, in collaboration with Pharma Innovation Forum Greece (PIF) and…
At the initiative of PhARMA Innovation Forum (PIF), a broad meeting was held with the Minister of Health, Mr. Adonis Georgiadis, with the participation of SFEE and other institutional pharmaceutical bodies, in a productive and positive atmosphere, with a shared recognition of the pressure exerted by the clawback on patients and the innovation ecosystem. The…
A dialogue between PIF and ENASEL on the truth behind access to innovation. As part of the ENASEL 2025 Annual Patient Conference, the session titled “Access to Innovation Under Threat: Debunking Myths, Revealing Facts” was successfully held, co-organized by PhARMA Innovation Forum (PIF) and ENASEL. The initiative aimed to highlight, through evidence-based dialogue and data…
“We want a Europe that does not just legislate, but truly innovates!” Ms. Labrina Barmpetaki, President of the PhARMA Innovation Forum (PIF), First Vice President of the Hellenic-American Chamber of Commerce, and Managing Director of AbbVie Greece, Cyprus & Malta, placed at the center of the 24th HealthWorld Conference, organized by the Hellenic-American Chamber of…
PhARMA Innovation (PIF) made a strong presence at the Bio3 Forum 2025 on Biotechnology, Bioinformatics & Bioeconomy, held on September 15–19 in Athens, under the theme “Fostering Collaboration in Industry & Academia.” The Forum served as a key reference point for the international scientific and business community, bringing together leading representatives from the pharmaceutical industry,…
A threat to patient access and public health PhARMA Innovation Forum (PIF) expresses its deep concern regarding the official data released by EKAPY (National Central Health Procurement Authority) – with a delay of more than a year – to our member companies. Once again, the figures reveal a complete derailment of the public budget for…
